Novoron Bioscience

Novoron's primary product, NOVO-118, has shown promising results in preclinical in vivo studies, demonstrating its ability to promote axonal regeneration and induce remyelination. Myelin, a protective covering around nerves, is crucial for rapid signal transmission and coordination of body movement. However, disease and injury can cause demyelination, overwhelming the body's natural remyelination process. Novoron's therapeutics aim to inhibit the LRP1 Rho pathway, thereby fostering axonal regeneration and remyelination.

The company operates in the biotechnology market, primarily serving clients in the medical and healthcare sectors, including research institutions and pharmaceutical companies. Novoron's business model revolves around the development and commercialization of its biologic therapeutics. The company generates revenue through partnerships, licensing agreements, and potential future sales of its therapeutic products.